Atlas Trials

TILT Biotherapeutics Ltd.

6 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch TILT Biotherapeutics Ltd.

RecordFirmDate
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma (NCT06961786)TILT Biotherapeutics Ltd.2025-06-25
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer (NCT06125197)TILT Biotherapeutics Ltd.2024-07-23
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 (NCT05222932)TILT Biotherapeutics Ltd.2023-03-08
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (NCT05271318)TILT Biotherapeutics Ltd.2022-05-17
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy (NCT04695327)TILT Biotherapeutics Ltd.2021-01-11
TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (NCT04217473)TILT Biotherapeutics Ltd.2020-02-26

Track TILT Biotherapeutics Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.